Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.30 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.30 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.30 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13566214 | 1.00 | FUCA1 (0.39) | FUCA1CA9CA12CA2L3MBTL1 | |
| SCHEMBL25498378 | 1.00 | FUCA1 (0.39) | FUCA1CA9CA12CA2L3MBTL1 | |
| SCHEMBL20202717 | 0.98 | FUCA1 (0.36) | FUCA1CA9CA12CA2L3MBTL1 | |
| SCHEMBL21907408 | 0.88 | L3MBTL1 (0.36) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL16640754 | 0.82 | FUCA1 (0.38) | FUCA1 | |
| SCHEMBL19293900 | 0.82 | L3MBTL1 (0.37) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL1105746 | 0.82 | L3MBTL1 (0.37) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL18026508 | 0.82 | L3MBTL1 (0.37) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL20226178 | 0.82 | L3MBTL1 (0.37) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL20307020 | 0.82 | L3MBTL1 (0.37) | L3MBTL1MAPTLGALS1LGALS3LGALS9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170248616-A1 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | Amydis, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, APBA1, CRYAA | FUCA1 134/4885CA9 3554/4885CA12 1995/4885 |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | APP, APBA1, CRYAA | FUCA1 134/4885CA9 3554/4885CA12 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.